Biomarkers and therapeutics targets

2024 ACTIVITY INDICATORS

  • 3 European projects: EATRIS-Connect (HE), REMEDI4ALL (HE), EUGLOH 2.0 (HE)
  • 6 competitive projects led: ISCIII, CAM and MICINN
  • 5 private projects led
  • 2 clinical studies led
  • competitive HR contract
  • 9 publications
  • IF: 65.00
  • Q1 publications: 3 (33%)
  • D1 publications: 2 (22%)
  • Project Evaluators: 3 PI
  • Member of editorial committee: 2 PI
  • 2 patent families: 
    • 1 international (US and European) patent application protecting miR127 as a novel therapeutic target in chronic kidney disease. European Application 16382399.0
    • 1 European patent application: EP22383047.2 protecting microRNAs in colorectal cancer with application PCT/EP2023/080239.
  • 2 transfer agreements with companies
  • 6 host visitors and 12.8 months stay:
    • Universidad Politécnica de Madrid (Spain)

Milestones

  1. Biomarkers and new therapies in gastro-intestinal tumours: i) collaboration with AMADIX for diagnostic kit in pancreatic cancer, (RETOS-Collaboration); ii) biomarkers of response in drug repositioning in this tumour (REMEDi4ALL); iii) multimodal biomarkers (miRAmut) for prognosis in colorectal cancer, including radiomic markers, in collaboration with Quibim (DTS Project); iv) European positioning in diagnostic tools and identification of population at risk in these tumours, through the development and use of reliable artificial intelligence tools. v) MISSION IRYCIS 2030 for the development and efficiency of NK-CART cells in colorectal cancer.
  2. Useful biomarkers for personalised medicine in clear cell renal carcinoma i) Identification of molecular signatures including non-coding RNAs and radiomic parameters predictive of response to new lines of treatment in this tumour context. 2nd consecutive ISCIII project). ii) Doctoral thesis (FI22/00312). iii) Consolidation as an expert group in radiobiology at national and European level through collaboration with ESTRO (European Society for Radiation Oncology). iv) Introduction of new transcriptomic methodologies (spatial transcriptomics) with a competitive European project (CANSERV).
  3. European reference group in multi-omics and multimodal biomarkers leading to the generation of reliable AI tools with clinical applicability, through national and European projects such as EATRIS Plus and EATRIS Connect, with leadership in the generation of tools such as MultiomicToolBox (https://motbx.eatris.eu/) or the digital hub.
  4. Reference group in drug repositioning and orphan drug designation, through European initiatives and projects such as REMEDi4ALL, in collaboration with policy makers (European Commission), regulatory agencies (EMEA) and patient organisations (PEOF, EURORDIS, POP), in tumour and rare kidney disease contexts.
  5. Scientific management of the Spanish node of the Translational Medicine Infrastructure EATRIS: leadership and European positioning of the Spanish node in EATRIS made up of 33 institutions, leadership in initiatives at national and European level in 'Citizen and patient participation', 'Climate change and health' and 'Digital transformation of health systems'.

Bibliometrics

  Articles Accum. FI Mean FI Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2020 14 77.19 12.87 11 79 4 29
2021 18 93.99 15.67 14 78 3 17
2022 13 106.48 8.19 12 92 3 23
2023 17 107.12 7.14 13 76 4 24
2024 9 65.00 10.83 6 67 2 22
  71 449.78 10.94 56 79 16 23

* Only original articles, editorials, guidelines and reviews

Networks and alliances

  • RICORS2040 (KIDNEY DISEASE)
  • EATRIS-European Infrastructure for Translational Medicine
  • ReTBioH-Red de Biobancos
  • AMADIX
  • Grupo AMPHARMA
  • European alliance of medical research infrastructures (EU-AMRI)
  • QUIBIM
  • International Consortium for Personalised Medicine (ICPerMed)
  • European Partnership for personalised medicine (EP PerMed)
  • PEOF: Patient Engagement Open Forum
  • COST Action EU-CardioRNA
  • CIFRA_COR-CM: Consorcio para el estudio del fracaso renal y su impacto en la patología cardiovascular